Beacon Capital Management LLC Boosts Stake in Stryker Corporation $SYK

Beacon Capital Management LLC lifted its holdings in Stryker Corporation (NYSE:SYK) by 31.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135 shares of the medical technology company’s stock after buying an additional 32 shares during the period. Beacon Capital Management LLC’s holdings in Stryker were worth $53,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC raised its stake in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Moody National Bank Trust Division purchased a new position in Stryker during the first quarter worth about $212,000. BTC Capital Management Inc. raised its stake in Stryker by 6.7% during the first quarter. BTC Capital Management Inc. now owns 2,741 shares of the medical technology company’s stock worth $1,020,000 after purchasing an additional 171 shares during the period. Fifth Third Wealth Advisors LLC raised its stake in Stryker by 23.5% during the first quarter. Fifth Third Wealth Advisors LLC now owns 5,190 shares of the medical technology company’s stock worth $1,932,000 after purchasing an additional 986 shares during the period. Finally, Abner Herrman & Brock LLC raised its stake in Stryker by 2.0% during the first quarter. Abner Herrman & Brock LLC now owns 32,514 shares of the medical technology company’s stock worth $12,103,000 after purchasing an additional 634 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.20% of the company’s stock.

Stryker Trading Up 0.1%

Shares of SYK stock opened at $368.83 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock has a market capitalization of $141.01 billion, a P/E ratio of 48.85, a price-to-earnings-growth ratio of 2.66 and a beta of 0.93. The company has a 50 day moving average price of $385.71 and a 200 day moving average price of $379.18. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s payout ratio is 44.50%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Evercore ISI lifted their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Needham & Company LLC lifted their price target on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Wells Fargo & Company lifted their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Fourteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.